These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 20525642)

  • 1. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment.
    Seiler S; Reichart B; Roth D; Seibert E; Fliser D; Heine GH
    Nephrol Dial Transplant; 2010 Dec; 25(12):3983-9. PubMed ID: 20525642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients.
    Viaene L; Bammens B; Meijers BK; Vanrenterghem Y; Vanderschueren D; Evenepoel P
    Nephrol Dial Transplant; 2012 May; 27(5):2017-22. PubMed ID: 22025115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.
    Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
    Nephrol Dial Transplant; 2009 Sep; 24(9):2792-6. PubMed ID: 19395730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ankle brachial index as a predictor for mortality in patients with chronic kidney disease and undergoing haemodialysis.
    Chen SC; Chang JM; Hwang SJ; Tsai JC; Liu WC; Wang CS; Lin TH; Su HM; Chen HC
    Nephrology (Carlton); 2010 Apr; 15(3):294-9. PubMed ID: 20470297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
    Brandenburg VM; Schlieper G; Heussen N; Holzmann S; Busch B; Evenepoel P; Vanholder R; Meijers B; Meert N; Fassbender WJ; Floege J; Jahnen-Dechent W; Ketteler M
    Nephrol Dial Transplant; 2010 Aug; 25(8):2672-9. PubMed ID: 20172849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications.
    Damasiewicz MJ; Toussaint ND; Polkinghorne KR
    Nephrology (Carlton); 2011 Mar; 16(3):261-8. PubMed ID: 21265930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship?
    Olauson H; Qureshi AR; Miyamoto T; Barany P; Heimburger O; Lindholm B; Stenvinkel P; Larsson TE
    Nephrol Dial Transplant; 2010 Sep; 25(9):3033-8. PubMed ID: 20368304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease?
    Peiskerová M; Kalousová M; Kratochvílová M; Dusilová-Sulková S; Uhrová J; Bandúr S; Malbohan IM; Zima T; Tesar V
    Kidney Blood Press Res; 2009; 32(4):276-83. PubMed ID: 19797911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
    Toussaint ND; Pedagogos E; Tan SJ; Badve SV; Hawley CM; Perkovic V; Elder GJ
    Nephrology (Carlton); 2012 Jul; 17(5):433-44. PubMed ID: 22574672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic value of apolipoproteins A and B in the clinical course of patients with chronic kidney disease previous to dialysis].
    Cerezo I; Fernández N; Romero B; Fernández-Carbonero E; Hernández-Gallego R; Caravaca F
    Nefrologia; 2009; 29(6):540-7. PubMed ID: 19935998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients.
    Kirkpantur A; Balci M; Gurbuz OA; Afsar B; Canbakan B; Akdemir R; Ayli MD
    Nephrol Dial Transplant; 2011 Apr; 26(4):1346-54. PubMed ID: 20813767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease].
    Ravera M; Paoletti E
    Ital Heart J Suppl; 2004 Jun; 5(6):436-44. PubMed ID: 15471148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.
    Sato T; Tominaga Y; Ueki T; Goto N; Matsuoka S; Katayama A; Haba T; Uchida K; Nakanishi S; Kazama JJ; Gejyo F; Yamashita T; Fukagawa M
    Am J Kidney Dis; 2004 Sep; 44(3):481-7. PubMed ID: 15332221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients.
    Noordzij M; Korevaar JC; Bos WJ; Boeschoten EW; Dekker FW; Bossuyt PM; Krediet RT
    Nephrol Dial Transplant; 2006 Sep; 21(9):2513-20. PubMed ID: 16799173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF-23: the rise of a novel cardiovascular risk marker in CKD.
    Heine GH; Seiler S; Fliser D
    Nephrol Dial Transplant; 2012 Aug; 27(8):3072-81. PubMed ID: 22851630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum adiponectin and cardiovascular risk in chronic kidney disease and kidney transplantation.
    Chitalia N; Raja RB; Bhandara T; Agrawal P; Kaski JC; Jha V; Banerjee D
    J Nephrol; 2010; 23(1):77-84. PubMed ID: 20091490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes predicted by phosphorous in chronic kidney disease: a retrospective CKD-inception cohort study.
    Smith DH; Johnson ES; Thorp ML; Petrik A; Yang X; Blough DK
    Nephrol Dial Transplant; 2010 Jan; 25(1):166-74. PubMed ID: 19671593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.
    Szczech LA; Bregman DB; Harrington RA; Morris D; Butcher A; Koch TA; Goodnough LT; Wolf M; Onken JE
    Nephrol Dial Transplant; 2010 Jul; 25(7):2368-75. PubMed ID: 20466657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor 23 and the bone-vascular axis: lessons learned from animal studies.
    Zoppellaro G; Faggin E; Puato M; Pauletto P; Rattazzi M
    Am J Kidney Dis; 2012 Jan; 59(1):135-44. PubMed ID: 22070851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of renal function and cardiac biomarkers (NT-proBNP and Troponin) in determining mortality and cardiac outcome in atheromatous renovascular disease.
    Chrysochou C; Manzoor S; Wright J; Roberts SA; Wood G; McDowell G; Kalra PA
    Kidney Blood Press Res; 2009; 32(5):373-9. PubMed ID: 19887825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.